Seminars in Nuclear Medicine
Volume 37, Issue 6 , Pages 429-439 , November 2007

FLT: Measuring Tumor Cell Proliferation In Vivo With Positron Emission Tomography and 3′-Deoxy-3′-[18F]Fluorothymidine

References 

  1. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: A major problem in the diagnostics of oncological patients. Eur J Nucl Med. 1996;23:1409–1415
  2. Metser U, Even-Sapir E. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): Accumulated data from four years of experience with PET/CT. Semin Nucl Med. 2007;37:206–222
  3. Faneyte IF, Schrama JG, Peterse JL, et al. Breast cancer response to neoadjuvant chemotherapy: Predictive markers and relation with outcome. Br J Cancer. 2003;88:406–412
  4. Takeuchi H, Ozawa S, Ando N, et al. Cell-cycle regulators and the Ki-67 labeling index can predict the response to chemoradiotherapy and the survival of patients with locally advanced squamous cell carcinoma of the esophagus. Ann Surg Oncol. 2003;10:792–800
  5. Chang J, Ormerod M, Powles TJ, et al. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer. 2000;89:2145–2152
  6. Grzybicki DM, Moore SA. Implications of prognostic markers in brain tumors. Clin Lab Med. 1999;19:833–847
  7. Brown DC, Gatter KC. Ki67 protein: The immaculate deception?. Histopathology. 2002;40:2–11
  8. van Diest PJ, van der Wall E, Baak JP. Prognostic value of proliferation in invasive breast cancer: A review. J Clin Pathol. 2004;57:675–681
  9. Pugsley JM, Schmidt RA, Vesselle H. The Ki-67 index and survival in non-small cell lung cancer: A review and relevance to positron emission tomography. Cancer J. 2002;8:222–233
  10. Martin B, Paesmans M, Mascaux C, et al. Ki-67 expression and patients survival in lung cancer: Systematic review of the literature with meta-analysis. Br J Cancer. 2004;91:2018–2025
  11. Vesselle H, Grierson J, Muzi M, et al. In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: Correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res. 2002;8:3315–3323
  12. Buck AK, Halter G, Schirrmeister H, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med. 2003;44:1426–1431
  13. Yap CS, Czernin J, Fishbein MC, et al. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Chest. 2006;129:393–401
  14. Yamamoto Y, Nishiyama Y, Ishikawa S, et al. Correlation of (18)F-FLT and (18)F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2007;
  15. Choi SJ, Kim JS, Kim JH, et al. [18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging. 2005;32:653–659
  16. Chen W, Cloughesy T, Kamdar N, et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med. 2005;46:945–952
  17. Saga T, Kawashima H, Araki N, et al. Evaluation of primary brain tumors with FLT-PET: usefulness and limitations. Clin Nucl Med. 2006;31:774–780
  18. Buck AK, Bommer M, Stilgenbauer S, et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res. 2006;66:11055–11061
  19. Kenny LM, Vigushin DM, Al-Nahhas A, et al. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: Evaluation of analytical methods. Cancer Res. 2005;65:10104–10112
  20. Troost EG, Vogel WV, Merkx MA, et al. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med. 2007;48:726–735
  21. Been LB, Elsinga PH, de Vries J, et al. Positron emission tomography in patients with breast cancer using (18)F-3′-deoxy-3′-fluoro-l-thymidine ((18)F-FLT)—a pilot study. Eur J Surg Oncol. 2006;32:39–43
  22. Buck AK, Hetzel M, Schirrmeister H, et al. Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging. 2005;32:525–533
  23. Pio BS, Park CK, Pietras R, et al. Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol. 2006;8:36–42
  24. Kenny L, Coombes RC, Vigushin DM, et al. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[(18)F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging. 2007;
  25. Herrmann K, Wieder HA, Buck AK, et al. Early response assessment using 3′-deoxy-3′-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin’s lymphoma. Clin Cancer Res. 2007;13:3552–3558
  26. Been LB, Suurmeijer AJ, Elsinga PH, et al. 18F-fluorodeoxythymidine PET for evaluating the response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcomas. J Nucl Med. 2007;48:367–372
  27. Martiat P, Ferrant A, Labar D, et al. In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin’s lymphoma using positron emission tomography. J Nucl Med. 1988;29:1633–1637
  28. Shields AF, Mankoff DA, Link JM, et al. Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med. 1998;39:1757–1762
  29. Wells P, Gunn RN, Alison M, et al. Assessment of proliferation in vivo using 2-[(11)C]thymidine positron emission tomography in advanced intra-abdominal malignancies. Cancer Res. 2002;62:5698–5702
  30. Eary JF, Mankoff DA, Spence AM, et al. 2-[C-11]thymidine imaging of malignant brain tumors. Cancer Res. 1999;59:615–621
  31. Shields AF, Graham MM, Kozawa SM, et al. Contribution of labeled carbon dioxide to PET imaging of carbon-11-labeled compounds. J Nucl Med. 1992;33:581–584
  32. Shields AF, Mankoff D, Graham MM, et al. Analysis of 2-carbon-11-thymidine blood metabolites in PET imaging. J Nucl Med. 1996;37:290–296
  33. Mankoff DA, Shields AF, Graham MM, et al. A graphical analysis method to estimate blood-to-tissue transfer constants for tracers with labeled metabolites. J Nucl Med. 1996;37:2049–2057
  34. Mankoff DA, Shields AF, Graham MM, et al. Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: Compartmental model and mathematical analysis. J Nucl Med. 1998;39:1043–1055
  35. Mankoff DA, Shields AF, Link JM, et al. Kinetic analysis of 2-[11C]thymidine PET imaging studies: Validation studies. J Nucl Med. 1999;40:614–624
  36. Wells JM, Mankoff DA, Eary JF, et al. Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: Preliminary patient results. Mol Imaging. 2002;1:145–150
  37. Wells JM, Mankoff DA, Muzi M, et al. Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: Compartmental model investigation and mathematical analysis. Mol Imaging. 2002;1:151–159
  38. Hartmann H, Vogt MW, Durno AG, et al. Enhanced in vitro inhibition of HIV-1 replication by 3′-fluoro-3′-deoxythymidine compared to several other nucleoside analogs. AIDS Res Hum Retroviruses. 1988;4:457–466
  39. Kong XB, Zhu QY, Vidal PM, et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother. 1992;36:808–818
  40. Flexner C, van der Horst C, Jacobson MA, et al. Relationship between plasma concentrations of 3′-deoxy-3′-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials. J Infect Dis. 1994;170:1394–1403
  41. Turcotte E, Wiens LW, Grierson JR, et al. Toxicology evaluation of radiotracer doses of 3′-deoxy-3′-[18F]fluorothymidine (18F-FLT) for human PET imaging: Laboratory analysis of serial blood samples and comparison to previously investigated therapeutic FLT doses. BMC Nucl Med. 2007;7:3
  42. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334–1336
  43. Grierson JR, Shields AF. Radiosynthesis of 3′-deoxy-3′-[(18)F]fluorothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol. 2000;27:143–156
  44. Rasey JS, Grierson JR, Wiens LW, et al. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210–1217
  45. Toyohara J, Waki A, Takamatsu S, et al. Basis of FLT as a cell proliferation marker: Comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol. 2002;29:281–287
  46. Schwartz JL, Tamura Y, Jordan R, et al. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med. 2003;44:2027–2032
  47. Wagner M, Seitz U, Buck A, et al. 3′-[18F]fluoro-3′-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res. 2003;63:2681–2687
  48. Dittmann H, Dohmen BM, Kehlbach R, et al. Early changes in [18F]FLT uptake after chemotherapy: An experimental study. Eur J Nucl Med Mol Imaging. 2002;29:1462–1469
  49. Barthel H, Cleij MC, Collingridge DR, et al. 3′-deoxy-3′-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res. 2003;63:3791–3798
  50. Sugiyama M, Sakahara H, Sato K, et al. Evaluation of 3′-deoxy-3′-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J Nucl Med. 2004;45:1754–1758
  51. Oyama N, Ponde DE, Dence C, et al. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J Nucl Med. 2004;45:519–525
  52. Leyton J, Latigo JR, Perumal M, et al. Early detection of tumor response to chemotherapy by 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography: The effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res. 2005;65:4202–4210
  53. Kawai H, Toyohara J, Kado H, et al. Acquisition of resistance to antitumor alkylating agent ACNU: Aa possible target of positron emission tomography monitoring. Nucl Med Biol. 2006;33:29–35
  54. van Waarde A, Been LB, Ishiwata K, et al. Early response of sigma-receptor ligands and metabolic PET tracers to 3 forms of chemotherapy: an in vitro study in glioma cells. J Nucl Med. 2006;47:1538–1545
  55. Yang YJ, Ryu JS, Kim SY, et al. Use of 3′-deoxy-3′-[18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors. Eur J Nucl Med Mol Imaging. 2006;33:412–419
  56. Apisarnthanarax S, Alauddin MM, Mourtada F, et al. Early detection of chemoradioresponse in esophageal carcinoma by 3′-deoxy-3′-3H-fluorothymidine using preclinical tumor models. Clin Cancer Res. 2006;12:4590–4597
  57. Buck AK, Kratochwil C, Glatting G, et al. Early assessment of therapy response in malignant lymphoma with the thymidine analogue [(18)F]FLT. Eur J Nucl Med Mol Imaging. 2007;(in press)
  58. Grierson JR, Schwartz JL, Muzi M, et al. Metabolism of 3′-deoxy-3′-[F-18]fluorothymidine in proliferating A549 cells: Validations for positron emission tomography. Nucl Med Biol. 2004;31:829–837
  59. Munch-Petersen B, Cloos L, Tyrsted G, et al. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J Biol Chem. 1991;266:9032–9038
  60. Lu L, Samuelsson L, Bergstrom M, et al. Rat studies comparing 11C-FMAU, 18F-FLT, and 76Br-BFU as proliferation markers. J Nucl Med. 2002;43:1688–1698
  61. Shields AF, Lim K, Grierson J, et al. Utilization of labeled thymidine in DNA synthesis: Studies for PET. J Nucl Med. 1990;31:337–342
  62. Barthel H, Perumal M, Latigo J, et al. The uptake of 3′-deoxy-3′-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging. 2005;32:257–263
  63. Muzi M, Mankoff DA, Grierson JR, et al. Kinetic modeling of 3′-deoxy-3′-fluorothymidine in somatic tumors: Mathematical studies. J Nucl Med. 2005;46:371–380
  64. Muzi M, Vesselle H, Grierson JR, et al. Kinetic analysis of 3′-deoxy-3′-fluorothymidine PET studies: Validation studies in patients with lung cancer. J Nucl Med. 2005;46:274–282
  65. Muzi M, Spence AM, O’Sullivan F, et al. Kinetic analysis of 3′-deoxy-3′-18F-fluorothymidine in patients with gliomas. J Nucl Med. 2006;47:1612–1621
  66. Wells P, West C, Jones T, et al. Measuring tumor pharmacodynamic response using PET proliferation probes: The case for 2-[(11)C]-thymidine. Biochim Biophys Acta. 2004;1705:91–102
  67. Krohn KA, Mankoff DA, Muzi M, et al. True tracers: Comparing FDG with glucose and FLT with thymidine. Nucl Med Biol. 2005;32:663–671
  68. Sherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem. 1988;263:8350–8358
  69. Wintersberger E, Rotheneder H, Grabner M, et al. Regulation of thymidine kinase during growth, cell cycle and differentiation. Adv Enzyme Regul. 1992;32:241–254
  70. Hengstschlager M, Knofler M, Mullner EW, et al. Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells. J Biol Chem. 1994;269:13836–13842
  71. Mikulits W, Hengstschlager M, Sauer T, et al. Overexpression of thymidine kinase mRNA eliminates cell cycle regulation of thymidine kinase enzyme activity. J Biol Chem. 1996;271:853–860
  72. Ito M, Conrad SE. Independent regulation of thymidine kinase mRNA and enzyme levels in serum-stimulated cells. J Biol Chem. 1990;265:6954–6960
  73. Leyton J, Alao JP, Da Costa M, et al. In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography. Cancer Res. 2006;66:7621–7629
  74. Leyton J, Lockley M, Aerts JL, et al. Quantifying the activity of adenoviral E1A CR2 deletion mutants using renilla luciferase bioluminescence and 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography imaging. Cancer Res. 2006;66:9178–9185
  75. Schwartz JL, Tamura Y, Jordan R, et al. Effect of p53 activation on cell growth, thymidine kinase-1 activity, and 3′-deoxy-3′fluorothymidine uptake. Nucl Med Biol. 2004;31:419–423
  76. Machulla HJ, Blocher A, Kuntzsch M, et al. Simplified labeling approach for synthesizing 3′-Deoxy-3′-[18F] fluorothymidine ([18F] FLT). J Radioanalytical Nucl Chem. 2000;243:843–846
  77. Wodarski C, Eisenbarth J, Weber K, et al. Synthesis of 3′-deoxy-3′-[[18]F] fluoro-thymidine with 2, 3′-anhydro-5′-O-(4, 4′-dimethoxytrityl)-thymidine. J Label Compounds Radiopharmaceuticals. 2000;43:1211–1218
  78. Vesselle H, Schmidt RA, Pugsley JM, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res. 2000;6:3837–3844
  79. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data (Generalizations). J Cereb Blood Flow Metab. 1985;5:584–590
  80. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1–7
  81. Grierson JR, Wiens L, Peterson L, et al: A SepPak unit for batch processing serial blood plasma samples for PET. J Label Compd Radiopharm In press 2007
  82. Shields AF, Briston DA, Chandupatla S, et al. A simplified analysis of [18F]3′-deoxy-3′-fluorothymidine metabolism and retention. Eur J Nucl Med Mol Imaging. 2005;32:1269–1275
  83. Vesselle H, Grierson J, Peterson LM, et al. 18F-Fluorothymidine radiation dosimetry in human PET imaging studies. J Nucl Med. 2003;44:1482–1488
  84. Hays MT, Watson EE, Thomas SR, et al. MIRD dose estimate report no. 19: Radiation absorbed dose estimates from (18)F-FDG. J Nucl Med. 2002;43:210–214
  85. FDA. Food and Drug Administration Code of Federal Regulations. 21 CFR. 1991;361-1:290–291
  86. Vesselle HJ, Miraldi FD. FDG PET of the retroperitoneum: normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls. Radiographics. 1998;18:805–823discussion 823-804
  87. Dittmann H, Dohmen BM, Paulsen F, et al. [18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging. 2003;30:1407–1412
  88. Cobben DC, Elsinga PH, Hoekstra HJ, et al. Is 18F-3′-fluoro-3′-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer?. J Nucl Med. 2004;45:1677–1682
  89. Ljungdahl-Stahle E, Guzenda E, Bottiger D, et al. Penetration of zidovudine and 3′-fluoro-3′-deoxythymidine into the brain, muscle tissue, and veins in cynomolgus monkeys: Relation to antiviral action. Antimicrob Agents Chemother. 1992;36:2418–2422
  90. Stahle L, Borg N. Transport of alovudine (3′-fluorothymidine) into the brain and the cerebrospinal fluid of the rat, studied by microdialysis. Life Sci. 2000;66:1805–1816
  91. Jacobs AH, Thomas A, Kracht LW, et al. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med. 2005;46:1948–1958
  92. Weber W, Bartenstein P, Gross MW, et al. Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors. J Nucl Med. 1997;38:802–808
  93. Ricci PE, Karis JP, Heiserman JE, et al. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography?. AJNR Am J Neuroradiol. 1998;19:407–413
  94. Wong TZ, van der Westhuizen GJ, Coleman RE. Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am. 2002;12:615–626
  95. Buchmann I, Neumaier B, Schreckenberger M, et al. [18F]3′-deoxy-3′-fluorothymidine-PET in NHL patients: Whole-body biodistribution and imaging of lymphoma manifestations–a pilot study. Cancer Biother Radiopharm. 2004;19:436–442
  96. Smyczek-Gargya B, Fersis N, Dittmann H, et al. PET with [18F]fluorothymidine for imaging of primary breast cancer: A pilot study. Eur J Nucl Med Mol Imaging. 2004;31:720–724
  97. Francis DL, Visvikis D, Costa DC, et al. Potential impact of [18F]3′-deoxy-3′-fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging. 2003;30:988–994
  98. van Westreenen HL, Cobben DC, Jager PL, et al. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. J Nucl Med. 2005;46:400–404
  99. Cobben DC, van der Laan BF, Maas B, et al. 18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET. J Nucl Med. 2004;45:226–231
  100. Cobben DC, Jager PL, Elsinga PH, et al. 3′-18F-fluoro-3′-deoxy-L-thymidine: A new tracer for staging metastatic melanoma?. J Nucl Med. 2003;44:1927–1932
  101. Cobben DC, Elsinga PH, Suurmeijer AJ, et al. Detection and grading of soft tissue sarcomas of the extremities with (18)F-3′-fluoro-3′-deoxy-L-thymidine. Clin Cancer Res. 2004;10:1685–1690

PII: S0001-2998(07)00089-X

doi: 10.1053/j.semnuclmed.2007.08.001

Seminars in Nuclear Medicine
Volume 37, Issue 6 , Pages 429-439 , November 2007

Article Tools

* Image Usage & Resolution